SCHEDULE 13D/A: CytoMed Therapeutics Chairman Amends Stake After Significant Share Gift

CytoMed Therapeutics Ltd's Chairman and Director, Choo Chee Kong, has filed an amended Schedule 13D, revealing a reduction in his beneficial ownership to 23.17% following a gift of 715,000 ordinary shares.

Summary

• Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Ltd, filed an Amendment No. 1 to Schedule 13D.
• The filing reports his current beneficial ownership of 2,673,325 Ordinary Shares, representing 23.17% of the Issuer's outstanding shares.
• This calculation is based on 11,540,000 Ordinary Shares outstanding.
• His beneficial ownership includes 2,075,310 shares held indirectly through Glorious Finance Limited (where he owns a 55% stake), 410,515 shares held by EP Capital Inc., and 187,500 shares held directly.
• On February 20, 2025, Mr. Choo Chee Kong transferred 715,000 Ordinary Shares, previously held by Glorious Finance Limited, to 28 Consultants Limited as a gift.
• The shares were originally acquired for investment purposes, either through capital contributions to the Issuer or public purchases with personal funds.
• Mr. Choo Chee Kong has sole voting and dispositive power over 598,015 Ordinary Shares and shared voting and dispositive power over 3,773,291 Ordinary Shares.
• The Reporting Person and the remaining shareholders of EP Capital may be deemed to be acting as a 'group' under Section 13(d)(3), sharing voting and dispositive power over 3,773,291 shares, though no formal agreement exists.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reported reduction in a significant insider's beneficial ownership, even though it was a gift. While the insider retains a substantial stake and role, the decrease in direct equity exposure is generally not viewed positively by investors.

Positives

• Mr. Choo Chee Kong maintains a substantial beneficial ownership stake of 23.17% in CytoMed Therapeutics Ltd, indicating continued significant alignment with the company's performance.
• His continued role as Chairman of the Board and Director suggests ongoing strategic involvement and oversight.

Negatives

• The filing reports a reduction in Mr. Choo Chee Kong's beneficial ownership due to the transfer of 715,000 Ordinary Shares as a gift, which decreases his direct and indirect exposure to the company's equity.

Risks

• The Reporting Person and other shareholders of EP Capital Inc. may be deemed to be acting as a 'group' under Section 13(d)(3) due to shared voting and dispositive power over 3,773,291 shares, despite the absence of a formal agreement, which could introduce ambiguity regarding coordinated actions.

Future Outlook

The Reporting Person has no current intention, plan, or proposal with respect to future actions concerning the Issuer, beyond his role as Chairman and Director, which may involve voting on or discussing matters related to the Issuer's corporate structure, business, or management.

Management Comments

• Mr. Choo Chee Kong acquired his Ordinary Shares for investment purposes, either in exchange for capital contributions to the Issuer or through public purchases on the open market with his personal funds.
• As Chairman of the Issuer and a member of the board of directors, Mr. Choo Chee Kong may be asked to vote on or discuss matters related to the Issuer's business, management, or corporate structure.

Industry Context

This Schedule 13D amendment primarily concerns an individual's ownership stake and does not provide broader industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders: The reduction in a significant insider's stake, even if a gift, might be viewed with caution by existing and potential shareholders, potentially impacting investor confidence.
• Management: The continued presence of Mr. Choo Chee Kong as Chairman and Director suggests stability in leadership and strategic direction.

Next Steps

• Mr. Choo Chee Kong will continue to serve as Chairman of the Board and Director of CytoMed Therapeutics Ltd, participating in discussions and voting on corporate matters.

Key Dates

Recommendation

Keywords

CytoMed Therapeutics Ltd, Schedule 13D, beneficial ownership, share transfer, Choo Chee Kong, insider ownership, corporate governance, Singapore, equity stake